Clinical trials: Tolerability
Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG
- Conditions
- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis
- Trial name
- NCT06753955
- Testing
- ART5803, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
Healthy Volunteers
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single and multiple intravenous doses of SPR206 when administered to healthy adult volunteers.
- Trial name
- NCT03792308
- Testing
- SPR206
- Where
- Australia
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Neurologic Diseases, General
Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.
- Trial name
- CBT101 (NCT07050316)
- Testing
- CBT101
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ceres Brain Therapeutics
Healthy Volunteers
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
This study will evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of ATH-399A in healthy adults and also evaluate the effect of food on ATH-399A in order to develop mechanism-based and/or…
- Trial name
- NCT06088784
- Testing
- ATH-399A, ATH-399A 10 mg, 5 mg ATH-399A capsule
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Microbial Colonization
Effect of Probiotics on Infant's Fecal Microbiota Composition
Randomized clinical trial to evaluate the effect of two probiotic strains which belong to Bifidobacterium Longum and Pediococcus pentosaceus species on fecal microbiota composition in healthy infants.
- Trial name
- BABYCARE (NCT05524649)
- Testing
- Food Supplement 1, Food Supplement 2
- Where
- 2 sites in Mexico, Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight,Obesity
Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants
ZT006 is an oral, long-acting glucagon-like peptide-1. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 in healthy, overweight and obese participants.
- Trial name
- NCT07307638
- Testing
- ZT006
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Volunteers
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023
This is a randomized, double-blind, placebo-controlled, multiple ascending dose study conducted at one study center in the United States.
- Trial name
- NCT03542435
- Testing
- SXC-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Promentis Pharmaceuticals, Inc.
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
- Trial name
- NCT07859735
- Testing
- Velzatinib
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
End-Stage Renal Disease (ESRD)
A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring…
- Trial name
- NCT06468826
- Testing
- Avacopan
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of repeated doses of a new investigational drug (ACU-4429) in healthy human subjects.
- Trial name
- NCT00942240
- Testing
- ACU-4429
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Parkinson's Disease
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
This two-part study will evaluate how safe LY3154207 is and the effects it has on the body. Part A will include healthy participants. Each participant will receive daily doses of LY3154207 or placebo for 14 days.
- Trial name
- NCT02562768
- Testing
- LY3154207
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Herpes
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.
- Trial name
- NCT07633197
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Health, Subjective
Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.
A phase I clinical trial to evaluate the safety and tolerability of a single-dose administration of BMI2004 Inj. (hyaluronidase, recombinant) in healthy adults
- Trial name
- NCT05922813
- Testing
- BMI2004, 0.9% NaCl
- Where
- South Korea
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- BMI Korea
Immunology
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract
The goal of this trial is to find out if Thymus Nuclear Extract is safe and well-tolerated in healthy men and women by testing three different dose levels and comparing the results to a placebo.
- Trial name
- NCT06795945
- Testing
- TPG1, TPG2, TPG3
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Migraine
Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers
This is a single-center, open-label, randomized, 3-way crossover study. Each subject will receive each of the three study treatments once, followed by in-clinic monitoring and extensive blood sample collection for plasma PK…
- Trial name
- NCT04969497
- Testing
- Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Zosano Pharma Corporation
Healthy
Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects
To assess the safety and tolerability of ascending single SC and IV doses of ATN-103 in healthy Japanese male subjects.
- Trial name
- ATN-103 (NCT00916110)
- Testing
- ATN-103
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Alzheimer Disease
Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531
The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects
- Trial name
- NCT00726115
- Testing
- SAM-531
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Dry Eye Syndromes
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Objective: To assess the safety and tolerability of the PRO-165 formulation on the ocular surface of ophthalmologically and clinically healthy subjects.
- Trial name
- PRO-165 (NCT03697876)
- Testing
- PRO-165, Artelac
- Where
- Mexico
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Healthy
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02325050
- Testing
- MVA-BN-Filo, Ad26. ZEBOV
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.